Kiersten V. Summers

Array ( [id] => 13607027 [patent_doc_number] => 20180355062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/029101 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837513 [patent_doc_number] => 20190022241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => NOVEL SEZ6 MODULATORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/005249 [patent_app_country] => US [patent_app_date] => 2018-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16005249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590083 [patent_doc_number] => 20180346590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTIGEN-BINDING MOLECULE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/001062 [patent_app_country] => US [patent_app_date] => 2018-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16001062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16053159 [patent_doc_number] => 20200188434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => A CELL COMPRISING A CHIMERIC ANTIGEN RECEPTOR (CAR) [patent_app_type] => utility [patent_app_number] => 16/613343 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267541 [patent_doc_number] => 11192953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Human monoclonal antibody human CD134 (OX40) and methods of making and using same [patent_app_type] => utility [patent_app_number] => 15/979305 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 26 [patent_no_of_words] => 32412 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17119699 [patent_doc_number] => 11130821 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Humanized anti-TF-antigen antibodies [patent_app_type] => utility [patent_app_number] => 15/976500 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 19802 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901875 [patent_doc_number] => 20190040142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => METHODS OF SCREENING FOR MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/974369 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386499 [patent_doc_number] => 20180244791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY [patent_app_type] => utility [patent_app_number] => 15/971127 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15971127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581495 [patent_doc_number] => 20210015897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => METHODS TO PRODUCE PEPTIDES, POLYPEPTIDES OR CELLS FOR MODULATING IMMUNITY [patent_app_type] => utility [patent_app_number] => 16/604970 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581495 [patent_doc_number] => 20210015897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => METHODS TO PRODUCE PEPTIDES, POLYPEPTIDES OR CELLS FOR MODULATING IMMUNITY [patent_app_type] => utility [patent_app_number] => 16/604970 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541281 [patent_doc_number] => 20200407694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => TARGETED GENE INTEGRATION OF CRS INHIBITOR GENES FOR IMPROVED IMMUNE CELLS THERAPY [patent_app_type] => utility [patent_app_number] => 16/755093 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172718 [patent_doc_number] => 11572415 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Multivalent FV antibodies [patent_app_type] => utility [patent_app_number] => 15/950733 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 23 [patent_no_of_words] => 19239 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826615 [patent_doc_number] => 20190016792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES [patent_app_type] => utility [patent_app_number] => 15/947377 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15947377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826687 [patent_doc_number] => 20190016828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES [patent_app_type] => utility [patent_app_number] => 15/947424 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15947424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13476521 [patent_doc_number] => 20180289803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => ANTI-PD-L1-ANTI-TIM-3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/945011 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15945011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328503 [patent_doc_number] => 20180215789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Concurrent Chemotherapy and Immunotherapy [patent_app_type] => utility [patent_app_number] => 15/938129 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15938129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328446 [patent_doc_number] => 20200299412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTI-PD-L1/ANTI-PD-1 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC BISPECIFIC ANTIBODY AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/498223 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649693 [patent_doc_number] => 20200087376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY [patent_app_type] => utility [patent_app_number] => 16/496144 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 159634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -119 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444201 [patent_doc_number] => 20180273643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 15/918034 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504819 [patent_doc_number] => 20180303952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => CD147 ANTIBODIES, ACTIVATABLE CD147 ANTIBODIES, AND METHODS OF MAKING AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/917404 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15917404 [rel_patent_id] =>[rel_patent_doc_number] =>)